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Presence of anti-rituximab antibodies predicts 
infusion-related reactions in patients with 
systemic lupus erythematosus
Rituximab (RTX) is a chimeric monoclonal anti-CD20 anti-
body used in the treatment of various rheumatic diseases.1 
Although generally well tolerated, infusion-related reactions 
(IRR) represent the most common adverse event associated 
with treatment and are difficult to predict. In patients under-
going treatment for rheumatoid arthritis, the incidence of IRR 
is quoted as 3%–4%2 3; however, in systemic lupus erythema-
tosus (SLE) this is significantly higher at 19%.4 To date, few 
studies have assessed the role antidrug antibodies (ADA) play 
in the lack of response or development of IRR to RTX in SLE. 
Here, we investigate how the presence of ADA relates to IRR 
and effectiveness of RTX therapy in SLE.
Fifty-seven patients fulfilling American College of Rheuma-
tology criteria were recruited from the lupus clinic at Univer-
sity College London Hospital, UK. All patients were receiving 
RTX for active SLE (British Isles Lupus Assessment Group 
[BILAG] A or 2B scores) for the first time. Confirmed IRR 
were recorded in electronic health records. Baseline character-
istics including complement C3 (C3), double-stranded DNA 
antibody titres (dsDNA) and BILAG score were recorded at 
the time of treatment and at each subsequent clinic visit. CD19 
positive lymphocyte (CD19) levels were measured at 1 and 6 
months following treatment. IRR were classified in accordance 
with Common Terminology Criteria for Adverse Events v4 
criteria (online supplementary table 1).5 Presence of ADA was 
assessed via a bridging electrochemiluminescence assay using 
biotinylated and ruthenylated RTX as capture and detection. 
Χ2 with Bonferroni correction was used to compare categor-
ical differences between ADA+ and ADA- groups. Paired t-test 
was used to assess for differences immediately prior to and at 
6 months following treatment.
As shown in table 1, ADA were identified in 37% of patients 
following treatment. ADA+ patients were younger both at 
diagnosis (p=0.03) and at the time of first treatment with RTX 
(p<0.001). In spite of low overall numbers, ADA were more 
commonly seen in males (p=0.04). There was no significant 
difference in concomitant treatment, disease manifestation 
and ethnicity. At the time of treatment, there was no difference 
in C3, dsDNA titres or BILAG. Figure 1 demonstrates that 
at 6 months post-treatment, ADA- patients show a significant 
increase in C3 levels (p=0.003) and reduction in dsDNA anti-
body binding (p=0.008) in keeping with effective response 
to treatment. In ADA+ patients, although normalisation of 
C3 was seen at 6 months (p=0.007), there was no observed 
improvement in dsDNA titres (p=0.96). Both ADA+ and ADA- 
patients displayed a significant improvement in global BILAG 
score 6 months after treatment (p<0.0001). There was no 
difference in CD19 between ADA+ and ADA- patients at either 
1 or 6 months post-treatment. Of the 57 patients recruited, 
25 patients underwent retreatment with RTX (18 ADA+ and 7 
ADA- patients). All ADA+ patients developed IRR, whereas no 
IRR was reported in those who were ADA- (p<0.001). Severe 
reactions resulting in hospitalisation were seen in three cases 
in which ADA titres were >1500 IU. In one such case, subse-
quent treatment with ofatumumab (a fully humanised anti-
CD20 monoclonal antibody) was well tolerated without the 
occurrence of further IRR.
We demonstrate that ADA to RTX are common in those under-
going treatment for SLE and have a clear association with subse-
quent IRR. Contrary to previous studies,6 our findings suggest that 
CD19 count is not affected by ADA, however the presence of ADA 
appeared to impair normalisation of dsDNA titres following treat-
ment. If validated, these findings may support routine screening 
for ADA prior to treatment with RTX, thus potentially identifying 
patients at risk of developing IRR and prompting greater caution 
and enhanced surveillance. In the context of high ADA titres, this 
may necessitate the use of an alternate B-cell depleting agent (such 
as ofatumumab).
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Table 1 Patient characteristics
ADA positive
N=21
ADA 
negative
N=36 P value
Age at diagnosis, years (SD) 22.0 (7.9) 30.0 (11.8) <0.001***
Age at time of treatment, years (SD) 31.9 (9.1) 42.9 (11.1) 0.03*
Disease duration, months (SD) 119 (76) 151 (108) NS
Gender (Female:Male) (%) 16:5 (76:24) 34:2 (94:6) 0.04*
Ethnicity, n (%)
  Afro-Caribbean 5 (24) 6 (17) NS
  Caucasian 9 (43) 19 (53) NS
  South Asian 3 (14) 6 (17) NS
  East Asian 3 (14) 2 (5) NS
  Other 1 (5) 3 (8) NS
Indication for treatment, n (%)
  Nephritis 10 (48) 7 (19) NS
  Arthritis 5 (24) 11 (31) NS
  Haematological 3 (14) 2 (6) NS
  Neuro-psychiatric 0 (0) 1 (3) NS
  Serositis 1 (5) 3 (8) NS
  Cutaneous 6 (29) 9 (25) NS
  Other 3 (14) 3 (8) NS
Additional treatment, n (%)
  Hydroxychloroquine 10 (48) 20 (56) NS
  Azathioprine 5 (24) 5 (14) NS
  Mycophenolate mofetil 4 (19) 4 (11) NS
  Methotrexate 0 (0) 4 (11) NS
  Prednisolone 17 (81) 27 (75) NS
  Cyclophosphamide† 15 (71) 22 (61) NS
Disease activity at the time of 
treatment
  Complement C3 (g/L) (SD) 0.76 (0.29) 0.69 (0.24) NS
  Anti-dsDNA titres (IU) (SD) 411.7 (651.6) 699.8 (874.2) NS
  Global BILAG score (SD) 15.8 (10.2) 13.5 (5.6) NS
Disease activity 6 months post-
treatment
  Complement C3 (g/L) (SD) 0.91 (0.27) 0.83 (0.24) NS
  Anti-dsDNA titres (IU) (SD) 201.4 (369.6) 682.0 
(1009.0)
0.04*
  Global BILAG score (SD) 6.4 (5.4) 7.4 (5.4) NS
*p<0.05; ***p<0.001.
†Given in combination with rituximab therapy.
ADA, antidrug antibody; BILAG, British Isles Lupus Assessment Group; dsDNA, 
double-stranded DNA; NS, not significant.
 o
n
 9 M
ay 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2019-215200 on 28 M
arch 2019. Downloaded from
 
2 Ann Rheum Dis Month 2019 Vol 0 No 0
Letter
2Bioanalysis, Immunogenicity & Biomarkers, IVIVT RD Platform Technology & Science, 
GlaxoSmithKline Plc, Philadelphia, Pennsylvania, USA
Correspondence to Professor Claudia Mauri, Centre for Rheumatology, Division of 
Medicine, London WC1E 6JF, UK;  c. mauri@ ucl. ac. uk
Handling editor Josef S Smolen
Collaborators The ABIRISK Consortium.
Contributors CW, MM, EJ and CM were involved in the design of the study and 
data interpretation. CW, ES and MM performed the research, collected, analysed 
and interpreted the data. DAI provided BILAG information; AS performed ADA 
assays. CW, MM, EJ and CM wrote the manuscript. CW, MM are joint first authors. 
All authors approved reviewed and approved the manuscript’s content before 
submission.
Funding The study was performed as part of the Innovative Medicines Initiative 
Joint Undertaking under grant agreement no 115303, resources of which are 
composed of financial contribution from the European Union’s Seventh Framework 
Program (FP7/2007–2013) and European Federation of Pharmaceutical Industries 
and Associations (EFPIA) in kind contribution. CW and CM are funded by LUPUS UK 
(176255; 174935). CW is funded by Versus Arthritis (549143). MM was funded by a 
Wellcome Trust grant awarded to CM (090406/Z/09/Z).
Competing interests None declared.
Patient consent for publication Obtained.
Ethics approval Ethics approval for this study was approved by the South Central 
- Hampshire B Research Ethics Committee (Ref 14/SC/1200)
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement There are no unpublished data relating to this study.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published 
by BMJ.
 ► Additional material is published online only. To view please visit the journal 
online (http:// dx. doi. org/ 10. 1136/ annrheumdis- 2019- 215200).
CW and MM are joint first authors.
Figure 1 Complement C3 levels significantly improve at 6 months post-treatment with RTX in ADA- (A) and ADA+ patients (B). Although a 
significant improvement in dsDNA binding was seen in in those who are ADA- at 6 months post-treatment (p=0.008) (C), this was not seen in 
those who were ADA+ (p=0.96) (D). A significant improvement in global BILAG score was seen in both (E) ADA- (p<0.0001) and (F) ADA+ patients 
(p<0.0001). No significant difference in CD19 positive lymphocyte count was seen at either 1 (G) and 6 (H) months post-treatment regardless of ADA 
status. ADA+ patients undergoing retreatment with RTX all developed IRR (I). The most common type of reaction observed was CTCAE type 2 with 
more severe reactions seen in those with higher ADA titres (J). ADA, antidrug antibody; CTCAE, Common Terminology Criteria for Adverse Events; IRR, 
infusion-related reactions; RTX, rituximab.
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